VYNE furnishes Q2 results for June 30, 2025 and announces board departures

Rhea-AI Filing Summary

VYNE Therapeutics furnished a press release reporting financial results for the quarter ended June 30, 2025; that press release is attached as Exhibit 99.1. The filing states the exhibit is being furnished and not "filed" for purposes of Section 18 of the Exchange Act. The report itself does not include the financial figures in this 8-K.

The registrant also disclosed that Christine Borowski, Ph.D. and Anthony Bruno resigned from the board effective immediately, each leaving their committee roles; the company stated the resignations were not due to any disagreement with the company or board and expressed thanks for their contributions.

Positive

• Press release of quarterly results was furnished as Exhibit 99.1, signaling timely disclosure of financial results to investors.
• Resignations stated as not due to disagreement, reducing immediate governance concern about board disputes.

Negative

• Two board members resigned effective immediately, creating potential committee and oversight vacancies.
• Filing does not include financial figures—investors must refer to Exhibit 99.1 for the quarter ended June 30, 2025 to assess results.

Insights

Corporate Governance Expert

TL;DR: Two independent directors resigned; departures appear orderly and unrelated to disputes but create immediate committee vacancies.

The simultaneous resignations of two board members reduce board continuity and remove a member from the Compensation Committee and both from the Nominating and Corporate Governance Committee, which could require prompt recruitment or committee reassignments. The filing explicitly states the departures were not due to disagreements, which limits governance red flags. The effect on oversight depends on the board's remaining composition and any planned director appointments, none of which are provided in this filing.

Securities Analyst

TL;DR: The company furnished quarter-end results via press release but did not include financial figures in this filing; two director resignations reported.

From a market-materiality perspective, the filing primarily notifies investors that a press release with financial results for the quarter ended June 30, 2025 exists as Exhibit 99.1; the 8-K itself does not present revenues, earnings, or guidance. The board departures are disclosed as non-contentious, suggesting limited immediate operational impact. Without the underlying financials or disclosure of replacements, the filing offers limited new data for valuation or credit analysis.

false 0001566044 0001566044 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

VYNE Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38356		45-3757789
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

685 Route 202/206 N., Suite 301

Bridgewater, New Jersey 08807

(Address of principal executive offices, including Zip Code)

(800) 775-7936

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		VYNE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, VYNE Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report.

The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Directors

On August 11, 2025, Christine Borowski, Ph.D. provided notice to the board of directors (the “Board”) of her resignation as member of the Board and as a member of the Nominating and Corporate Governance Committee effective immediately. On August 13, 2025, Anthony Bruno provided notice to the Board of his resignation as member of the Board and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee effective immediately. Mr. Bruno’s and Dr. Borowski’s resignations were not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. The Company thanks Mr. Bruno and Dr. Borowski for their contributions to the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated August 14, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VYNE THERAPEUTICS INC.
Date: August 14, 2025
	By:	/s/ Mutya Harsch
		Mutya Harsch
		Chief Legal Officer and General Counsel

2

FAQ

What did VYNE (VYNE) disclose in this Form 8-K?

The company furnished a press release reporting financial results for the quarter ended June 30, 2025 as Exhibit 99.1 and disclosed two director resignations.

Who resigned from VYNE's board?

Christine Borowski, Ph.D. and Anthony Bruno resigned as members of the board; Mr. Bruno also left the Compensation Committee and both left the Nominating and Corporate Governance Committee.

Were the resignations due to disagreements with VYNE?

No. The filing explicitly states the resignations were not the result of any dispute or disagreement with the company or the board.

Where can I find the actual financial results mentioned?

The financial results are disclosed in the press release attached as Exhibit 99.1; the 8-K text does not include the numerical results.

Does the 8-K say the press release is "filed" for Section 18 purposes?

No. The filing states the information and Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.